Kendall Capital Management Purchases Shares of 7,395 ANI Pharmaceuticals, Inc. $ANIP

Kendall Capital Management purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 7,395 shares of the specialty pharmaceutical company’s stock, valued at approximately $612,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. KBC Group NV purchased a new position in shares of ANI Pharmaceuticals during the first quarter valued at about $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the first quarter worth about $28,000. Hantz Financial Services Inc. lifted its position in shares of ANI Pharmaceuticals by 70.3% in the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares in the last quarter. Kemnay Advisory Services Inc. bought a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $48,000. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals during the second quarter valued at approximately $50,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 2.5%

Shares of NASDAQ ANIP opened at $75.35 on Friday. The firm’s 50-day moving average price is $80.36 and its 200-day moving average price is $78.88. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of 16.24 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. The trade was a 4.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Meredith Cook sold 500 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the sale, the vice president owned 74,424 shares in the company, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 18,987 shares of company stock valued at $1,546,405. 8.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Weiss Ratings downgraded ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $105.83.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.